Epigenetic Biomarkers in Cardiovascular Diseases

Area of Science:

• Biomedical Science
• Genetics
• Cardiology

Background:

• Cardiovascular diseases (CVDs) are a leading global cause of mortality, impacting quality of life and healthcare costs.
• Epigenetic dysregulation is increasingly linked to CVD progression, offering new avenues for prevention and treatment.
• Advances in big data and methodology enable personalized epigenetic mapping for tailored diagnosis and therapy.

Purpose of the Study:

• To review current discoveries and controversies surrounding epigenetic biomarkers in cardiovascular diseases.
• To explore the potential of epigenetic biomarkers for improving diagnosis, prognosis, and therapy in CVD patients.

Main Methods:

• Literature review of recent advancements in epigenetic research related to cardiovascular diseases.
• Analysis of the role of epigenetic mechanisms, biomarkers, and pharmacoepigenetics in CVD.
• Discussion of the clinical applicability and challenges of epigenetic biomarkers.

Main Results:

• Epigenetic biomarkers are emerging as valuable tools for CVD diagnosis and prognosis due to their accessibility and feasible detection methods.
• Pharmacoepigenetics offers personalized drug response prediction and tailored therapy based on individual epigenetic profiles.
• Current evidence highlights the potential of epigenetics in understanding and managing cardiovascular diseases.

Conclusions:

• Epigenetic biomarkers hold significant promise for enhancing cardiovascular disease management.
• Large-scale, multicenter studies are essential to validate the clinical utility of specific epigenetic biomarkers.
• Further research into epigenetic mechanisms can lead to improved diagnostic, prognostic, and therapeutic strategies for cardiovascular patients.